Physician profile
Paul Jack Deramo
NPI 1346545837
$182,943.70
in general payments reported to CMS, 2019-2025
27 companies · $92K in 2025
The $92K reported for 2025 was more than what 99% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $1,375 · 2021: $3,646 · 2022: $2,056 · 2023: $13K · 2024: $71K · 2025: $92K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $110K · Travel and Lodging: $53K · Food and Beverage: $9,468 · Long Term Medical Supply Or Device Loan: $1,303 · Honoraria: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $110,072.50 |
| Travel and Lodging | $53,424.79 |
| Food and Beverage | $9,468.16 |
| Long Term Medical Supply Or Device Loan | $1,303.20 |
| Honoraria | $1,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $159,585.85 | 2022-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Medical Device Business Services, INC. | $6,792.68 | 2024-2025 | Vistaseal, Stratafix |
| Allergan, INC. | $4,691.92 | 2019-2022 | |
| Abbvie INC. | $3,764.64 | 2023-2025 | Natrelle Saline-Filled Breast Implants, Alloderm |
| Axogen | $3,181.74 | 2021-2025 | Axoguard Nerve Protector, Axoguard Nerve Connector, Avance Nerve Graft |
| Rti Surgical, INC | $1,200.00 | 2025 | |
| Ethicon US, LLC | $1,186.55 | 2023-2025 | Vistaseal, Megadyne, Stratafix |
| Checkpoint Surgical, INC | $404.32 | 2021-2024 | Checkpoint Stimulators |
| Aroa Biosurgery Incorporated | $314.75 | 2022-2023 | |
| Davol INC. | $251.45 | 2022-2025 | Phasix Mesh, Arista |
| Teleflex LLC | $246.09 | 2022 | |
| Acera Surgical, INC. | $172.02 | 2023-2024 | Restrata Wound Matrix |
| Stryker Corporation | $161.77 | 2021 | |
| Depuy Synthes Sales INC. | $159.21 | 2022 | |
| Solventum Corporation | $134.87 | 2025 | Activ.A.C., Prevena, Snap |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mentor Worldwide LLC | $120.95 | 2022-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Solta Medical, A Division of Bausch Health US, LLC | $119.39 | 2025 | |
| Tela Bio, INC. | $112.28 | 2022-2024 | Ovitex 2s |
| Coopersurgical, INC. | $67.66 | 2024-2025 | Insorb |
| Polynovo North America LLC | $59.54 | 2022-2023 | |
| Kci USA, INC. | $47.79 | 2021-2023 | Promogran Prisma, Activ.A.C., V.A.C. Dermatac |
| Cook Biotech Incorporated | $42.14 | 2023 | Oasis |
| Heron Therapeutics, INC. | $40.83 | 2022 | |
| Musculoskeletal Transplant Foundation INC. | $32.34 | 2021-2023 | |
| Innovation Technologies INC | $19.38 | 2022 | |
| Medtronic, INC. | $19.06 | 2023 | Closurefast |
| Kerecis Limited | $14.48 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Deramo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.